Brickell Biotech Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 1.94
Dividend & YieldN/A$ (N/A)
Beta 0.08
Market capitalization 8.08M
Operating cash flow -28.45M
ESG Scores unknown

Company description

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 12.56M -9.74M -3.47M 1.02M
Total Cashflows From Investing Activities -12k 32.51M 4.48M -36k
Net Borrowings -1.28M 2.59M 437k
Total Cash From Financing Activities -1.29M 2.64M 38.44M 32.95M
Change To Operating Activities -356k -3.89M 1.82M -1.58M
Issuance Of Stock 45k 47k 38M 33M
Net Income -9.24M -23.88M -20.91M -39.47M
Change In Cash 2.67M -835k 22.88M -3.23M
Effect Of Exchange Rate
Total Cash From Operating Activities 3.97M -35.98M -20.03M -36.15M
Depreciation 49k 28k 10k 22k
Change To Account Receivables
Other Cashflows From Financing Activities -50k
Change To Netincome 464k -77k 2.52M 3.86M
Capital Expenditures -12k -7k -23k -36k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -9.24M -23.88M -20.91M -39.47M
Net Income -9.24M -23.88M -20.91M -39.47M
Selling General Administrative 6.38M 11.73M 11.58M 12.42M
Gross Profit -2.07M -12.3M -9.39M -27.83M
Ebit -8.45M -24.03M -20.98M -40.24M
Operating Income -8.45M -24.03M -20.98M -40.24M
Interest Expense -1.09M -2.1M -69k -69k
Income Tax Expense
Total Revenue 10.89M 7.92M 1.82M 404k
Cost Of Revenue 12.96M 20.21M 11.22M 28.23M
Total Other Income ExpenseNet -782k 150k 63k 770k
Net Income From Continuing Ops -9.24M -23.88M -20.91M -39.47M
Net Income Applicable To Common Shares -15.17M -13.6M -20.91M -39.47M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 21.84M 10.57M 6.5M 4.81M
Total Stockholder Equity -71.62M 7.57M 27.14M 24.91M
Other Current Liabilities 8.12M 1.79M
Total Assets 8.75M 18.14M 33.63M 29.72M
Common Stock 6k 85k 536k 1.19M
Other Current Assets 95k
Retained Earnings -71.62M -84.98M -105.89M -145.37M
Treasury Stock -28k
Cash 8.07M 7.23M 30.11M 26.88M
Total Current Liabilities 20.09M 10.5M 6.35M 4.81M
Other Stockholder Equity -28k
Property, Plant, and Equipment 37k 175k 104k 117k
Total Current Assets 8.27M 17.97M 33.53M 29.6M
Net Tangible Assets -72.06M 7.57M 27.14M 24.91M
Net Receivables
Accounts Payable 4.07M 2.25M 568k 1.6M


Insider Transactions

Here are the insider transactions of stock shares related to Brickell Biotech Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
HARDY REGINALD LPurchase at price 0.66 - 0.67 per share.D2021-07-26Chairman of the Board200k
MCAVOY DAVID RPurchase at price 0.67 per share.D2021-07-23General Counsel18.12k
CHADHA DEEPAKPurchase at price 0.82 - 0.83 per share.D2021-05-19Officer15.2k
MCAVOY DAVID RPurchase at price 0.80 per share.D/I2021-05-17General Counsel26.6k
SKLAWER ANDREW D.Purchase at price 0.80 per share.D2021-05-17Chief Operating Officer15.38k
MCAVOY DAVID RD2021-03-16General Counsel25k
BRETON JOSED2021-03-16Officer15k
CHADHA DEEPAKD2021-03-16Officer25k
SKLAWER ANDREW D.D2021-03-16Chief Operating Officer20k
BROWN ROBERT BUSARDPurchase at price 1.18 per share.D2021-03-15Chief Executive Officer100k
HARDY REGINALD LStock Award(Grant) at price 0.78 per share.D2021-01-01Chairman of the Board47.44k
MCAVOY DAVID RPurchase at price 0.83 - 0.84 per share.D/I2020-09-18General Counsel22.53k
VERU DENNISON TPurchase at price 0.80 - 0.81 per share.D2020-09-16Director30k
HARDY REGINALD LStock Award(Grant) at price 0.81 per share.D2020-09-15Chairman of the Board15.23k
LYONS GARY AStock Award(Grant) at price 0.81 per share.D2020-09-15Director11.93k
SAMANT VIJAY BStock Award(Grant) at price 0.81 per share.D2020-09-15Director10.49k
VERU DENNISON TStock Award(Grant) at price 0.81 per share.D2020-09-15Director13.58k
VERU DENNISON TD2020-09-14Director19.64k
VERU DENNISON TI2020-08-31Director788
HARDY REGINALD LD2020-08-31Chairman of the Board883
LYONS GARY AD2020-08-31Director692
SAMANT VIJAY BD2020-08-31Director609
VERU DENNISON TI2020-07-31Director787
HARDY REGINALD LD2020-07-31Chairman of the Board882
LYONS GARY AD2020-07-31Director692
SAMANT VIJAY BD2020-07-31Director608
VERU DENNISON TI2020-06-30Director787
HARDY REGINALD LD2020-06-30Chairman of the Board883
LYONS GARY AD2020-06-30Director691
SAMANT VIJAY BD2020-06-30Director608
MCAVOY DAVID RD2020-06-22General Counsel30.43k
CHADHA DEEPAKD2020-06-22Officer26.09k
SKLAWER ANDREW D.D2020-06-22Chief Operating Officer13.04k
BROWN ROBERT BUSARDD2020-06-22Chief Executive Officer86.96k
VERU DENNISON TD2020-06-03Director19.64k
HARDY REGINALD LD2020-06-03Chairman of the Board22.02k
LYONS GARY AD2020-06-03Director17.26k
SAMANT VIJAY BD2020-06-03Director15.18k
VERU DENNISON TI2020-05-29Director7.12k
HARDY REGINALD LD2020-05-29Chairman of the Board7.98k
LYONS GARY AD2020-05-29Director6.26k
SAMANT VIJAY BD2020-05-29Director5.5k
ARMISTICE CAPITAL L.L.C.Sale at price 0.88 per share.I2019-01-10Beneficial Owner of more than 10% of a Class of Security2.19M
ARMISTICE CAPITAL L.L.C.Purchase at price 1.19 - 1.21 per share.I2018-06-28Beneficial Owner of more than 10% of a Class of Security1.28M
ARMISTICE CAPITAL L.L.C.Purchase at price 1.21 - 1.26 per share.D2018-06-27Beneficial Owner of more than 10% of a Class of Security51.8k
ARMISTICE CAPITAL L.L.C.Purchase at price 1.25 - 1.27 per share.I2018-06-22Beneficial Owner of more than 10% of a Class of Security18.36k
ARMISTICE CAPITAL L.L.C.Purchase at price 1.15 - 1.20 per share.I2018-06-18Beneficial Owner of more than 10% of a Class of Security42.84k
ARMISTICE CAPITAL L.L.C.Purchase at price 1.06 - 1.23 per share.I2018-06-13Beneficial Owner of more than 10% of a Class of Security670.9k
ARMISTICE CAPITAL L.L.C.Purchase at price 1.42 - 1.46 per share.I2018-01-22Beneficial Owner of more than 10% of a Class of Security100k
MERTON ROBERT CPurchase at price 1.75 per share.D2017-11-10Director85.7k
RAMOS ANTHONY ALANSale at price 2.17 per share.D2017-03-27Officer4.25k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Brickell Biotech Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Brickell Biotech Inc

Here is the result of two systematic investment strategies applied to Brickell Biotech Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Brickell Biotech Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Brickell Biotech Inc:

Brickell Biotech Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -79.75% on the backtest period.

Performance at glance

Performance

-79.75 %

Latent gain

-1389.58 $

Invested capital

1742.38 $

Annualized return

-19.45 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Brickell Biotech Inc

This is the result of two momentum investment strategies applied to Brickell Biotech Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Brickell Biotech Inc

The following chart shows all the entries opened by the momentum investment system on Brickell Biotech Inc:

Brickell Biotech Inc momentum entries
  • The first momentum investment strategy would give -75.88% of return on Brickell Biotech Inc. That represents -3417.22$ of latent gain with 4503.22$ of employed capital.
  • The second momentum investment strategy would give -71.51% of return on Brickell Biotech Inc. That represents -1791.88$ of latent gain with 2505.88$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-75.88 %

Latent gain

-3417.22 $

Invested capital

4503.22 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

-71.51 %

Latent gain

-1791.88 $

Invested capital

2505.88 $

Annualized return

-19.75 %

Momentum equity curve on Brickell Biotech Inc

The following chart shows the equity curve of the two momentum strategies applied to Brickell Biotech Inc:

Brickell Biotech Inc momentum equity

Note: the dividends potentially given by Brickell Biotech Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Brickell Biotech Inc

The following chart shows the employed capital evolution of the two momentum strategies on Brickell Biotech Inc since the beginning:

Brickell Biotech Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Brickell Biotech Inc

Buy the dip entry openings on Brickell Biotech Inc

Brickell Biotech Inc

The performance achieved by the robo-advisor on Brickell Biotech Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Brickell Biotech Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Brickell Biotech Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Brickell Biotech Inc

The following chart shows the result of the investment strategy applied to Brickell Biotech Inc:

Brickell Biotech Inc

Note: the dividends potentially given by Brickell Biotech Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Brickell Biotech Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Brickell Biotech Inc:

Brickell Biotech Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Brickell Biotech Inc

In this section, I will compare the three previous investment strategies applied to Brickell Biotech Inc.

Equity curve comparison on Brickell Biotech Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Brickell Biotech Inc investment strategy comparison

Employed capital comparison on Brickell Biotech Inc

Brickell Biotech Inc investment comparison

Performance comparison on Brickell Biotech Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -79.75% -1389.58$ 1742.38$ -19.45%
Momentum 1 quarter -75.88% -3417.22$ 4503.22$ -19.66%
Momentum 2 quarters -71.51% -1791.88$ 2505.88$ -19.75%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

-19.45 %

Momentum 1Q

-19.75 %

Momentum 2Q

-19.75 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Brickell Biotech Inc:

Positive correlations

Most correlated stocks this year

  • Brickell Biotech Inc

  • Most correlated stocks last 3 months

  • Brickell Biotech Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • OSE IMMUNO

  • Note: The algorithm computes the probability of correlation between Brickell Biotech Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Brickell Biotech Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Brickell Biotech Inc
    Country United States
    City Boulder
    Address 5777 Central Avenue
    Phone 720 505 4755
    Website www.brickellbio.com
    FullTime employees 16
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker BBI
    Market www.nasdaq.com

    Brickell Biotech Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown